2020, Inc.

2020, Inc. delivers mobile ophthalmic clinical trial solutions, enhancing patient access to eye assessments through on-site evaluations, aimed at improving recruitment and data integrity in clinical research. Founded in 2014, 2020, Inc. is based in Boston, US, and specializes in mobile ophthalmic clinical trial solutions.

The company has successfully conducted five deals, with the most recent deal occurring on May 11, 2021. Their latest funding round was a GROWTH round, securing USD 3. 5 mn, matching their total raised amount of USD 3. 5 mn.

The founders include Ged Oneill and Howard Bornstein, with Alexis McLaughlin serving as the CEO. 20/20 Onsite specializes in delivering point-of-need ophthalmic clinical trial solutions, leveraging a mobile platform that brings eye assessments directly to participants. Their core offerings encompass comprehensive ophthalmic evaluations conducted on-site, thereby addressing the complexities associated with traditional clinical trial assessments. These services enhance patient recruitment, retention, and data accuracy by minimizing the need for participants to travel long distances, which is particularly beneficial for underserved populations.

The firm has supported over 34 clinical trials, demonstrating a commitment to meeting screening timelines and ensuring the integrity of ocular endpoints. Their clientele includes clinical research organizations (CROs) and sponsors in the pharmaceutical sector, primarily across North America, where they have conducted more than 85,000 eye exams, positioning themselves as a leader in mobile ophthalmic care. While specific financial data is not disclosed, the revenue model for 20/20 Onsite is based on contractual agreements with clinical sponsors and CROs, providing mobile ophthalmic services for clinical trials. These transactions are structured as service agreements, with clients paying for the delivery of eye care services at trial sites or directly to participants.

Revenue is generated through a fee-for-service model that includes pricing for comprehensive eye exams and associated data services, tailored to meet the specific needs of each study. The company’s innovative approach drives operational efficiencies and helps clients achieve significant cost savings in trial execution, emphasizing the value of their mobile solutions in enhancing the overall research process. In May 2021, 2020, Inc. raised USD 3.

5 mn in growth funding, part of an USD 8 mn growth round, to support the expansion of current consumer operations and increase its support for clinical trials. The company plans to introduce new products designed to enhance their mobile ophthalmic services, though specific launch dates have not been disclosed. Additionally, there are plans to expand into new markets, particularly targeting regions with underserved populations that would benefit from improved access to mobile eye care solutions.